⚕ GalenOps CRO console
← SITE007 (JPN)

SITE007-0147

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE007 (JPN) (Dr. Dubois) · consented 2022-08-17
Adverse events
8
Serious AEs
1
Open data queries
0
Luna dropout signal
–

Adverse events

moderate assessed 2026-08-18

Grade 2 Colitis — outcome: RECOVERED/RESOLVED; onset 2022-11-15 (study day 73); relationship: Y

moderate assessed 2026-08-18

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-01-30 (study day 149); relationship: N

moderate assessed 2026-08-18

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-04-28 (study day 237); relationship: N

mild assessed 2026-08-18

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-06-29 (study day 299); relationship: not assessed

severe serious assessed 2026-08-18

Grade 4 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-12-22 (study day 475); relationship: not assessed; serious criteria: life-threatening

moderate assessed 2026-08-18

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-12-23 (study day 476); relationship: N

moderate assessed 2026-08-18

Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2024-01-17 (study day 501); relationship: N

mild assessed 2026-08-18

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-03-05 (study day 549); relationship: not assessed

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.